86
Participants
Start Date
January 7, 2019
Primary Completion Date
May 29, 2020
Study Completion Date
June 30, 2022
Rilonacept
Rilonacept 320 mg (or 4.4 mg/kg in pediatric participants ≥12 and \<18 years old) SC , followed by 160 mg (or 2.2 mg/kg in pediatric participants ≥12 and \<18 years old) injections once weekly
Placebo
Placebo SC injections once weekly
GenesisCare - Cardiology Research, Doncaster East
Cardiology Consultants of Philadelphia, Yardley
Virginia Commonwealth University, Richmond
Arthritis and Rheumatology of Georgia, Atlanta
HeartCare Partners Clinical Research Unit, Milton
Cleveland Clinic, Cleveland
Cincinnati Children's Hospital Medical Center, Cincinnati
Minneapolis Heart Institute Foundation, Minneapolis
Mayo Clinic - PPDS, Rochester
The Loretto Hospital, Chicago
Intermountain Healthcare, Murray
Cedars-Sinai Medical Institute, Los Angeles
Swedish Medical Center, Seattle
University Of Vermont Medical Center, Burlington
Bnai Zion Medical Center, Haifa
Shaare Zedek Medical Center, Jerusalem
Galilee Medical Center, Nahariya
Sheba Medical Center at Tel-Hashomer, Ramat Gan
Ospedale Pediatrico Bambino Gesù, Rome
ASST Fatebenefratelli Sacco - Ospedale Fatebenefratelli e Oftalmico, Milan
Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin
Lead Sponsor
Kiniksa Pharmaceuticals (UK), Ltd.
INDUSTRY